A combination of blood stem cell and pancreatic islet cell transplant from an immunologically mismatched donor completely ...
Clinical Trials Arena on MSN
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial
In the trial, all six evaluable patients have remained insulin-free after receiving tegoprubart after islet transplantation.
Researchers at Karolinska Institutet have established a novel transplantation site for islets of Langerhans that enables long ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant Institute ...
Pluristyx's platform technology was developed specifically to overcome this challenge. This Breakthrough T1D collaboration will fund the use of precise gene editing to engineer Pluristyx's exclusively ...
In islet cell transplantation, beta cells are removed from a donor's pancreas and transferred into a person with type 1 diabetes. Beta cells are one type of cell found in the islets of the pancreas ...
Eledon Pharmaceuticals Inc (NASDAQ:ELDN) stock rose 3.3% in after-hours trading Tuesday following the release of encouraging preliminary results from a trial evaluating its experimental drug ...
The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback